Sjogren's Syndrome Clinical Trial
Official title:
Clinical and Laboratory Evaluation of the Autonomic Nervous System in Primary Sjogren's Syndrome
Background:
Sj(SqrRoot)(Delta)gren s Syndrome (SS) is an autoimmune disease that affects the glands that
produce saliva and tears, causing dry eyes and dry mouth.
Researchers do not know the exact cause of SS, but they believe that it may be caused by
abnormalities in the autonomic nervous system (ANS) that stimulate these glands.
Objectives:
To better understand ANS function in patients with SS.
To compare information about ANS function in healthy individuals and in patients with SS.
Eligibility:
Patients with Sj(SqrRoot)(Delta)gren s Syndrome who are 18 years of age and older, and who
are not pregnant or breastfeeding.
Participants will be asked to taper or discontinue the use of certain medications or dietary
supplements before the ANS testing.
Participants must be willing to discontinue the use of alcohol and tobacco 24 hours prior to
testing.
Design:
The study will require one inpatient admission and/or outpatient visits to the NIH Clinical
Center.
The following tests and procedures will be performed:
- Saliva, tear, and sweat production measurements to evaluate the function of glands.
- Testing of changes to the cardiovascular system, including blood pressure and blood flow
testing, and an electrocardiogram designed to evaluate hemodynamic changes controlled by
the ANS.
- Testing of changes to the gastrointestinal system, including a swallowing assessment
study, barium swallow study, and gastric emptying study designed to evaluate
gastrointestinal function controlled by the ANS.
- Tests to evaluate the ANS function in response to certain drugs (edrophonium, glucagon
and acetylcholine).
- Self-reported questionnaire on ANS function and emotional/psychological well-being.
Additional procedures and tests may include the following:
- Blood samples.
- Optional skin biopsy to study sweat glands and nerve supply of the skin.
Sj(SqrRoot)(Delta)gren s syndrome (SjS) is a systemic exocrinopathy that affects as high as 5
percent of the population. It is manifested predominantly as dry eyes, dry mouth, and
fatigue. The exocrinopathy can be encountered alone (primary SjS) in approximately one half
of the patients or in the presence of another autoimmune disorder such as rheumatoid
arthritis, systemic lupus erythematosus, or systemic sclerosis (secondary SjS). The most
widely accepted classification for SjS is the American-European consensus classification
criteria for SjS.(Vitali, Bombardieri et al. 2002)
Current understanding about the pathogenesis of SjS stems from the assumption that the
autoimmune destruction of the exocrine glands leads to their hypofunction and symptoms of
dryness. The existing evidence however does not fully support this assumption and cannot
explain the underlying pathogenic mechanisms of SjS for the following reasons: 1) Discordance
between severely affected function and abundance of histologically normal and ex vivo
functional salivary glands; 2) at least 20% of patients have no evidence of systemic
autoimmunity; 3) Animal models of SjS develop glandular dysfunction long before they develop
autoimmunity; 4) Dryness and related symptoms respond poorly to immunosuppressive, including
newer biologics, but fairly well to secretagogues such as pilocarpine. 5) No pathogenic
antibodies or target epitopes have been identified to date to unify the pathogenesis of the
syndrome.
All exocrine glands are innervated by the autonomic nervous system (ANS) and dysautonomia can
mimic the phenotype of SjS, particularly cardinal manifestations, such as xerostomia and
xerophthalmia. Thus we hypothesize that ANS dysfunction is central to the pathogenesis of SjS
and propose to systematically study the ANS function in our cohort of patients with primary
SjS compared with normative data from age and sex-matched controls. This protocol calls for a
comprehensive evaluation of autonomic function, using physiological, neuropharmacologic,
neurochemical, and imaging approaches, to identify consistent distinctive patterns of ANS
involvement in SjS and thereby improve the diagnosis and understanding of pathophysiologic
mechanisms of SjS.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT04968912 -
A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)
|
Phase 2 | |
Completed |
NCT03203382 -
Corneal Nerve Structure in Sjogren's
|
||
Completed |
NCT00809003 -
Assessment of Inflammatory and Functional Changes in the Ocular Surface Associated With Dry Eye Disease
|
N/A | |
Completed |
NCT00023491 -
Potential of Transplanted Stem Cells to Mature Into Salivary Gland and Cheek Cells
|
N/A | |
Completed |
NCT05005806 -
Fish Oil (Omega 3 ) in Sjogren's Syndrome
|
Phase 2/Phase 3 | |
Enrolling by invitation |
NCT03436576 -
Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye
|
Phase 3 | |
Terminated |
NCT04143841 -
Viveye Ocular Magnetic Neurostimulation System (OMNS) for the Management of Severe Dry Eye Disease
|
N/A | |
Completed |
NCT03611283 -
Topical Management of Xerostomia With Dry Mouth Products
|
N/A | |
Recruiting |
NCT06104124 -
A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity
|
Phase 3 | |
Recruiting |
NCT05115487 -
Evaluation of Hand Functions in Newly Diagnosed Primary Sjögren's Syndrome
|
||
Recruiting |
NCT06437652 -
An AI Algorithm for Lymphocyte Focus Score of Minor Salivary Gland Biopsy Samples for Diagnosing Sjogren's Syndrome
|
||
Recruiting |
NCT05383677 -
Anifrolumab Treatment for 24 Weeks in Patients With Primary Sjögren's Syndrome
|
Phase 2 | |
Not yet recruiting |
NCT03938207 -
Dry Eye Syndrome, Healthy Control, Sjögren's Syndrome and Other Inflammation Disease in Taiwan Biobank
|
||
Completed |
NCT04239521 -
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
|
||
Completed |
NCT04546542 -
Hydroxychloroquine Blood Levels in Primary Sjögren Syndrome Patients
|
||
Recruiting |
NCT05085431 -
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome
|
Early Phase 1 | |
Completed |
NCT01369589 -
An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness
|
Phase 1/Phase 2 | |
Completed |
NCT00001953 -
The Functioning of Immune and Hormonal Systems in Patients With Sjogren's Syndrome and in Healthy Volunteers
|
N/A | |
Completed |
NCT00001731 -
Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops
|
Phase 2 |